Rocket Pharmaceuticals (RCKT) PT Lowered to $56 at Stifel, Reiterates "Buy" Rating
Tweet Send to a Friend
Stifel analyst Dae Gon Ha lowered the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $56.00 (from $67.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
